Samumed closes $438mm Series A-6 round
Samumed LLC (small-molecule regenerative medicines) closed a $438mm Series A-6 round from undisclosed investors. The company says the current transaction puts its pre-money valuation at $12bn.
- Antisense, Oligonucleotides
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.